Long-term opioid use does not increase risk of Alzheimer’s disease

Published: 30-Oct-2017
Research & Development

A recent study from the University of Eastern Finland has shown opioid use is not associated with an increased risk of Alzheimer’s disease

Researchers did not find any risk neither for long-term use nor for higher cumulative doses. Opioids are powerful pain relieving drugs that act on the nervous system.

Published in Pain Medicine, the study is the most extensive one conducted on the topic so far.

A previous study from the US reported an association between high cumulative doses of opioids and an increased risk of dementia, but the Finnish study does not confirm this finding.

However, several adverse effects are related to opioid use, such as drowsiness and reduced alertness, and for this reason, opioid use should be restricted to the most severe pain conditions only.

Opioid use may also lead to addiction or tolerance to pain-relieving effects.

Opioid use was compared between Finnish persons with Alzheimer’s disease and their control persons without the disease.

The study was part of the nationwide register-based MEDALZ study and included 70,718 persons diagnosed with Alzheimer’s disease in Finland during 2005-2011, as well as 282,862 control persons.

References

  • H. Taipale, et al., “Is Alzheimer’s disease associated with previous opioid use?” Pain Medicine (2017).

  • Companies:
  • University of Eastern Finland
See more

You may also like

Drug Delivery

A thyroxine derivative enhances brain drug delivery

Read more
A new study from the University of Eastern Finland shows that the delivery of drugs into the brain, and especially into glial cells, can be enhanced with prodrugs that temporarily incorporate thyroxine or a thyroxine-like molecule

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

A thyroxine derivative enhances brain drug delivery

A new study from the University of Eastern Finland shows that the delivery of drugs into the brain, and especially into glial cells, can be enhanced with prodrugs that temporarily incorporate thyroxine or a thyroxine-like molecule
Research & Development

Research finds more efficient drug delivery within the brain using LAT1

A new study from the University of Eastern Finland has found by converting drug molecules temporarily into LAT1 prodrugs it can achieve higher concentrations at the target site
Research & Development

Research warns of negative antibiotic effect on mitochondria in humans

University of Eastern Finland has found that ciprofloxacin has dramatic effects on the mitochondrial genome
Research & Development

Psychotropic polypharmacy found to be common in Alzheimer’s disease

Up to half of people with Alzheimer’s disease (AD) use a psychotropic drug, and one in five uses two or more psychotropics concomitantly, according to a study conducted at the University of Eastern Finland
Research & Development

Antiepileptic drugs increase risk of Alzheimer’s and dementia

The use of antiepileptic drugs is associated with an increased risk of Alzheimer’s disease and dementia, according to a new study from the University of Eastern Finland and the German Center for Neurodegenerative Diseases, DZNE
Research & Development

Antidepressant use increases risk of head injuries among persons with Alzheimer’s disease

Antidepressant use is associated with an increased risk of head injuries and traumatic brain injuries among persons with Alzheimer’s disease, according to a new study from the University of Eastern Finland
Research & Development

Antiulcer drugs do not increase risk of Alzheimer’s disease

A recent study from the University of Eastern Finland shows the use of proton pump inhibitors does not increase the risk of Alzheimer’s disease
Subscribe now